CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-28 | Wahlstrom Mats Director | Grant or award | +29,994 | $2.08 | $63K | 40,000 |
| 2022-02-28 | Wahlstrom Mats Director | Option exercise · Stock Option (Right to Buy) | +29,994 | 0 | ||
| 2022-02-25 | Wahlstrom Mats Director | Grant or award | +10,006 | $11.64 | $116K | 10,006 |
| 2022-02-02 | Newcomer Lee Nisley Director | Grant or award · Stock Option (Right to Buy) | +54,000 | 54,000 | ||
| 2022-01-11 | Vexler Vladimir Chief Scientific Officer | Shares withheld for taxes | −3,583 | $14.36 | $51K | 107,421 |
| 2022-01-10 | Vexler Vladimir Chief Scientific Officer | Shares withheld for taxes | −4,150 | $14.30 | $59K | 111,004 |
| 2022-01-07 | HEALY JAMES Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-07 | STOLPER MARK Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-07 | TZOUMAKAS KIMBERLY JO Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-07 | Wahlstrom Mats Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-07 | HEALY JAMES Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-07 | STOLPER MARK Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-07 | TZOUMAKAS KIMBERLY JO Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-07 | Wahlstrom Mats Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2022-01-04 | Lanfear Dennis M President & CEO | Grant or award | +86,250 | 579,508 | ||
| 2022-01-04 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +402,500 | 402,500 | ||
| 2022-01-04 | Stilwell McDavid Chief Financial Officer | Grant or award | +40,000 | 73,138 | ||
| 2022-01-04 | Stilwell McDavid Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2022-01-04 | Vexler Vladimir Chief Scientific Officer | Grant or award | +40,000 | 115,154 | ||
| 2022-01-04 | Vexler Vladimir Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 |
Page 8 of 39 · 768 trades